U.S., Jan. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07343024) titled 'Methods of Identifying Effective Off-Guideline Treatments for Advanced Cancer Patients (CC N-of-1)' on Dec. 11, 2025.
Brief Summary: Many FDA-approved drugs are not available to patients with a particular cancer because there has been no successful clinical trial conducted for that drug against that cancer. In the absence of such a successful clinical trial, the drug is not included in the National Comprehensive Cancer Network (NCCN) guidelines list of approved drugs for that cancer. The absence of a drug in the NCCN Guidelines for a particular cancer is usually not an indication that the drug has been shown to be ineffective for pa...